# Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

> **NCT05226871** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Breast Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Cetuximab
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT05226871
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226871, "Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05226871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*